XOMA Corporation (XOMA): Price and Financial Metrics

XOMA Corporation (XOMA): $13.82

0.20 (-1.43%)

POWR Rating

Component Grades








Add XOMA to Watchlist
Sign Up

Industry: Biotech




#307 of 356

in industry

XOMA Price/Volume Stats

Current price $13.82 52-week high $26.00
Prev. close $14.02 52-week low $13.68
Day low $13.74 Volume 10,200
Day high $14.02 Avg. volume 34,619
50-day MA $15.36 Dividend yield N/A
200-day MA $18.39 Market Cap 158.56M

XOMA Stock Price Chart Interactive Chart >


  • Growth is the dimension where XOMA ranks best; there it ranks ahead of 61.27% of US stocks.
  • XOMA's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • XOMA ranks lowest in Momentum; there it ranks in the 9th percentile.

XOMA Stock Summary

  • XOMA's price/sales ratio is 44.56; that's higher than the P/S ratio of 96.51% of US stocks.
  • With a year-over-year growth in debt of -87.22%, XOMA CORP's debt growth rate surpasses just 1.63% of about US stocks.
  • As for revenue growth, note that XOMA's revenue has grown -90.16% over the past 12 months; that beats the revenue growth of merely 1.46% of US companies in our set.
  • Stocks that are quantitatively similar to XOMA, based on their financial statements, market capitalization, and price volatility, are CJJD, TASK, VINE, MEG, and EVGO.
  • XOMA's SEC filings can be seen here. And to visit XOMA CORP's official web site, go to www.xoma.com.

XOMA Valuation Summary

  • In comparison to the median Healthcare stock, XOMA's price/earnings ratio is 121.72% lower, now standing at -5.8.
  • XOMA's price/earnings ratio has moved up 5.7 over the prior 243 months.

Below are key valuation metrics over time for XOMA.

Stock Date P/S P/B P/E EV/EBIT
XOMA 2023-09-22 44.6 1.6 -5.8 -5.8
XOMA 2023-09-21 44.8 1.6 -5.9 -5.9
XOMA 2023-09-20 45.2 1.7 -5.9 -5.9
XOMA 2023-09-19 46.0 1.7 -6.0 -6.1
XOMA 2023-09-18 46.3 1.7 -6.1 -6.1
XOMA 2023-09-15 50.4 1.8 -6.6 -6.8

XOMA Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 82.99%.
  • Its year over year price growth rate is now at -42.77%.
  • The year over year cash and equivalents growth rate now stands at 26.71%.
XOMA's revenue has moved up $22,116,000 over the prior 33 months.

The table below shows XOMA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 40.486 21.653 9.793
2022-06-30 40.975 22.241 9.535
2022-03-31 40.893 22.583 12.043
2021-12-31 38.16 22.678 7.787
2021-09-30 29.797 9.714 5.429
2021-06-30 29.414 10.353 10.156

XOMA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XOMA has a Quality Grade of C, ranking ahead of 66.13% of graded US stocks.
  • XOMA's asset turnover comes in at 0.233 -- ranking 184th of 682 Pharmaceutical Products stocks.
  • DARE, WINT, and TCON are the stocks whose asset turnover ratios are most correlated with XOMA.

The table below shows XOMA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.233 1 0.187
2021-06-30 0.252 1 0.254
2021-03-31 0.277 1 0.222
2020-12-31 0.301 1 0.242
2020-09-30 0.025 1 -0.219
2020-06-30 0.116 1 -0.137

XOMA Price Target

For more insight on analysts targets of XOMA, see our XOMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $44.67 Average Broker Recommendation 1.67 (Moderate Buy)

XOMA Corporation (XOMA) Company Bio

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is based in Berkeley, California.

XOMA Latest News Stream

Event/Time News Detail
Loading, please wait...

XOMA Latest Social Stream

Loading social stream, please wait...

View Full XOMA Social Stream

Latest XOMA News From Around the Web

Below are the latest news stories about XOMA CORP that investors may wish to consider to help them evaluate XOMA as an investment opportunity.

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series

Yahoo | September 25, 2023

XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 9:30 AM ET. The conference is being held in New York, NY. The presentation can be accessed at https://bit.ly/3qJMUgT or by visiting the investor relations section of the company’s website at www.xoma.co

Yahoo | September 6, 2023

Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA),

Key Insights Significantly high institutional ownership implies XOMA's stock price is sensitive to their trading...

Yahoo | August 13, 2023

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Application in third quarter of 2023 EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent

Yahoo | August 8, 2023

XOMA Added to the Russell 2000® and Russell 3000® Indexes

EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000® and Russell 3000® Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Each year, the Russell indexes are reconstituted to capture the 4,0

Yahoo | June 23, 2023

Read More 'XOMA' Stories Here

XOMA Price Returns

1-mo N/A
3-mo -15.63%
6-mo N/A
1-year -20.07%
3-year -29.70%
5-year -17.54%
YTD -24.89%
2022 -11.75%
2021 -52.75%
2020 61.65%
2019 115.81%
2018 -64.47%

Continue Researching XOMA

Want to see what other sources are saying about XOMA Corp's financials and stock price? Try the links below:

XOMA Corp (XOMA) Stock Price | Nasdaq
XOMA Corp (XOMA) Stock Quote, History and News - Yahoo Finance
XOMA Corp (XOMA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!